S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
OTCMKTS:TRUMY

Terumo Stock Forecast, Price & News

$37.39
-0.09 (-0.24 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.71
Now: $37.39
$37.56
50-Day Range
$37.46
MA: $40.58
$43.92
52-Week Range
$25.80
Now: $37.39
$44.76
Volume11,385 shs
Average Volume40,269 shs
Market Capitalization$28.40 billion
P/E Ratio36.30
Dividend Yield0.49%
Beta0.38
Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The company operates through three segments: Cardiac and Vascular Company, General Hospital Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stent, intravascular ultrasound systems, drug-eluting stents, imaging catheters, and others; coils and stents for treating cerebral aneurysm, aspiration catheters and clot retrievers for treating ischemic stroke, and others; oxygenators, flow diverters, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The General Hospital Company segment provides infusion pumps, syringe pumps, solution sets, syringes, I.V. solutions, pain management products, nutritious food, adhesion barriers, blood glucose monitoring systems, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, automated blood collection systems, automated blood component processing systems, pathogen reduction technology, automated centrifugal apheresis systems, cell expansion system, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.
Terumo logo

Headlines

Terumo Enters 100th Anniversary Year
January 5, 2021 |  finance.yahoo.com
MicroVention-Terumo Announces New Leadership
September 22, 2020 |  finance.yahoo.com
UV light robot destroys coronavirus in 2 minutes
May 12, 2020 |  finance.yahoo.com
IceCure Continues Global Expansion to Freeze Tumors
April 20, 2020 |  www.prnewswire.com
Terumo Corporation (TRUMY)
March 26, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Medical & hospital equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TRUMY
Previous SymbolNASDAQ:TRUMY
CUSIPN/A
CIKN/A
Phone813-3374-8111
Employees26,438
Year Founded1964

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.79 billion
Cash Flow$1.52 per share
Book Value$9.14 per share

Profitability

Net Income$783.93 million

Miscellaneous

Market Cap$28.40 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.75 out of 5 stars

Medical Sector

1191st out of 1,972 stocks

Medical & Hospital Equipment Industry

5th out of 7 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$37.39
-0.09 (-0.24 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRUMY News and Ratings via Email

Sign-up to receive the latest news and ratings for TRUMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Terumo (OTCMKTS:TRUMY) Frequently Asked Questions

Is Terumo a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terumo in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Terumo stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRUMY, but not buy additional shares or sell existing shares.
View analyst ratings for Terumo
or view top-rated stocks.

What stocks does MarketBeat like better than Terumo?

Wall Street analysts have given Terumo a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Terumo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Terumo?

Terumo saw a decline in short interest during the month of February. As of February 12th, there was short interest totaling 7,600 shares, a decline of 30.9% from the January 28th total of 11,000 shares. Based on an average trading volume of 45,300 shares, the short-interest ratio is currently 0.2 days.
View Terumo's Short Interest
.

When is Terumo's next earnings date?

Terumo is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Terumo
.

How has Terumo's stock price been impacted by COVID-19 (Coronavirus)?

Terumo's stock was trading at $32.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TRUMY shares have increased by 14.3% and is now trading at $37.39.
View which stocks have been most impacted by COVID-19
.

Is Terumo a good dividend stock?

Terumo pays an annual dividend of $0.19 per share and currently has a dividend yield of 0.49%. The dividend payout ratio of Terumo is 18.27%. This payout ratio is at a healthy, sustainable level, below 75%.
View Terumo's dividend history.

Who are Terumo's key executives?

Terumo's management team includes the following people:
  • Mr. Shinjiro Sato, Pres, CEO & Director
  • Mr. Naoki Muto, Chief Accounting & Financial Officer and Exec. Officer
  • Mr. Hiroaki Kasukawa, CTO & Exec. Officer
  • Mr. Katsuya Takeuchi, Exec. Officer, Chief Information Officer & GM of IT Dept.
  • Kenichi Hata, Gen. Mang. of Investor Relations Department
  • Ms. Miho Mizuguchi, Exec. Officer, Chief Legal Officer and GM of Legal & Compliance Department
  • Atsuo Omagari, Gen. Mang. of Corp. Communication Department
  • Mr. Kyo Nishikawa, Sr. Exec. Officer, Chief HR Officer & Director
  • Mr. Toshiaki Takagi, Sr. Managing Exec. Officer & Director
  • Mr. Kazuaki Kitabatake, Managing Exec. Officer

Who are some of Terumo's key competitors?

What is Terumo's stock symbol?

Terumo trades on the OTCMKTS under the ticker symbol "TRUMY."

How do I buy shares of Terumo?

Shares of TRUMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Terumo's stock price today?

One share of TRUMY stock can currently be purchased for approximately $37.39.

How much money does Terumo make?

Terumo has a market capitalization of $28.40 billion and generates $5.79 billion in revenue each year. The company earns $783.93 million in net income (profit) each year or $1.04 on an earnings per share basis.

How many employees does Terumo have?

Terumo employs 26,438 workers across the globe.

When was Terumo founded?

Terumo was founded in 1964.

What is Terumo's official website?

The official website for Terumo is www.terumo.co.jp.

Where are Terumo's headquarters?

Terumo is headquartered at 2-44-1 Hatagaya Shibuya-ku, Tokyo M0, 151-0072.

How can I contact Terumo?

Terumo's mailing address is 2-44-1 Hatagaya Shibuya-ku, Tokyo M0, 151-0072. The company can be reached via phone at 813-3374-8111 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.